PCV82 Simulation of Long-Term Clinical Benefits and Costs of Add-On Therapy with Aliskiren in Hypertensive Patients with Diabetic Nephropathy- A German Statutory Health Insurance Perspective
Abstract
Authors
J.M. Graf von der Schulenburg D. Weycker E. Kaiser K. Neidhardt Y. Brede